AstraZeneca Tonocard discontinuation
AstraZeneca will discontinue Tonocard (tocainide) in U.S. Dec. 31. Approved in 1984 to treat severe irregular heartbeat, company says newer products now dominate market. Tonocard was one of original Astra Merck collaborations (1"The Pink Sheet" Nov. 7, 1994, p. 9). Merck currently manufacturers the drug for AstraZeneca. Worldwide sales in 2002 were approximately $1.2 mil., the bulk of which were in the U.S, AstraZeneca says...
You may also be interested in...
ASTRA COUNTING ON LONG-TERM INDICATION FOR PRILOSEC HELP PAY OFF $820 MIL. BUY-IN TO ASTRA MERCK; JOINT VENTURE SALES ARE $860 MIL THROUGH NINE MONTHS
Astra is looking to a long-term indication for Prilosec to help pay off its $820 mil. investment in Astra Merck, Inc.
A patient recruiter got 10 years in prison for his role in a scheme to convince seniors to get unneeded and expensive genetic tests. Nicholas McQuaid, acting assistant attorney general of the Justice Department’s Criminal Division, discussed the case.
Wall Street is worried that a cluster of recent negative regulatory events means tougher reviews going forward. That concern is probably overdone, but a year into the COVID pandemic is a good time to take stock of how FDA is doing.